Towards a point-of-care test for active tuberculosis: Obstacles and opportunities

Nature Reviews Microbiology

Volumn 9, Issue 3, 2011, Pages 204-213

  McNerney, Ruth ^a   Daley, Peter ^b  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^b MEMORIAL UNIVERSITY OF NEWFOUNDLAND   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL VIRULENCE; CHROMATOGRAPHY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; DISEASE MARKER; HUMAN; IMMUNOCHROMATOGRAPHY; NANOSENSOR; NONHUMAN; POINT OF CARE TESTING; PREDICTIVE VALUE; PRIORITY JOURNAL; RAMAN SPECTROMETRY; REVIEW; SENSITIVITY AND SPECIFICITY; TUBERCULOSIS;

HEALTH SERVICES ACCESSIBILITY; HUMANS; POINT-OF-CARE SYSTEMS; SENSITIVITY AND SPECIFICITY; TUBERCULOSIS; WORLD HEALTH;

EID: 79951846140     PISSN: 17401526     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrmicro2521     Document Type: Review

References (98)

1. WHO. Global tuberculosis control: WHO Report 2010 (WHO, Geneva, 2010).
2. WHO. Global tuberculosis control: surveillance, planning, financing (WHO, Geneva, 2009).
3. Fox, W., Ellard, G. A. & Mitchison, D. A. Studies on the treatment of tuberculosis undertaken by the British Medical Research Council tuberculosis units, 1946-1986, with relevant subsequent publications. Int. J. Tuberc. Lung Dis. 3, S231-S279 (1999). (Pubitemid 29481843)
4. Lienhardt, C. et al. Factors affecting time delay to treatment in a tuberculosis control programme in a sub-Saharan African country: the experience of The Gambia. Int. J. Tuberc. Lung Dis. 5, 233-239 (2001). (Pubitemid 32397601)
5. Golub, J. E. et al. Delayed tuberculosis diagnosis and tuberculosis transmission. Int. J. Tuberc. Lung Dis. 10, 24-30 (2006).
6. Rajeswari, R. et al. Factors associated with patient and health system delays in the diagnosis of tuberculosis in South India. Int. J. Tuberc. Lung Dis. 6, 789-795 (2002). (Pubitemid 34988049)
7. Salaniponi, F. M. et al. Care seeking behaviour and diagnostic processes in patients with smear-positive pulmonary tuberculosis in Malawi. Int. J. Tuberc. Lung Dis. 4, 327-332 (2000). (Pubitemid 30194107)
8. Storla, D. G., Yimer, S. & Bjune, G. A. A systematic review of delay in the diagnosis and treatment of tuberculosis. BMC Public Health 8, 15 (2008).
9. Lonnroth, K., Thuong, L. M., Linh, P. D. & Diwan, V. K. Delay and discontinuity-a survey of TB patients' search of a diagnosis in a diversified health care system. Int. J. Tuberc. Lung Dis. 3, 992-1000 (1999).
10. Keeler, E. et al. Reducing the global burden of tuberculosis: the contribution of improved diagnostics. Nature 444 (Suppl. 1), 49-57 (2006).
11. McNerney R. Symposium: Point-of-care tests for tuberculosis. Rev. Port. Pneumol. 16, 49-55 (2010).
12. Foulds, J. & O'Brien, R. New tools for the diagnosis of tuberculosis: the perspective of developing countries. Int. J. Tuberc. Lung Dis. 2, 778-783 (1998). (Pubitemid 28461990)
13. Steingart, K. R., Ramsay, A. & Pai, M. Optimizing sputum smear microscopy for the diagnosis of pulmonary tuberculosis. Expert Rev. Anti Infect. Ther. 5, 327-331 (2007). (Pubitemid 47050155)
14. Elliott, A. M. et al. Impact of HIV on tuberculosis in Zambia: a cross sectional study. BMJ 301, 412-415 (1990). (Pubitemid 20279231)
15. Golden, M. P. & Vikram, H. R. Extrapulmonary tuberculosis: an overview. Am. Fam. Physician 72, 1761-1768 (2005). (Pubitemid 41633285)
16. Perkins, M. D. & Kritski, A. L. Diagnostic testing in the control of tuberculosis. Bull. World Health Organ. 80, 512-513 (2002). (Pubitemid 34632836)
17. Steingart, K. R. et al. Commercial serological antibody detection tests for the diagnosis of pulmonary tuberculosis: a systematic review. PLoS Med. 4, e202 (2007).
18. Lemaire, J. F. & Casenghi, M. New diagnostics for tuberculosis: fulfilling patient needs first. J. Int. AIDS Soc. 13, 40 (2010).
19. Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin. Pharmacol. Ther. 69, 89-95 (2001).
20. Doherty, M., Wallis, R. S. & Zumla, A. Biomarkers for tuberculosis disease status and diagnosis. Curr. Opin. Pulm. Med. 15, 181-187 (2009).
21. Parida, S. K. & Kaufmann, S. H. The quest for biomarkers in tuberculosis. Drug Discov. Today 15, 148-157 (2010).
22. Jacobsen, M., Mattow, J., Repsilber, D. & Kaufmann, S. H. Novel strategies to identify biomarkers in tuberculosis. Biol. Chem. 389, 487-495 (2008). (Pubitemid 351874187)
23. Wallis, R. S. et al. Biomarkers for tuberculosis disease activity, cure, and relapse. Lancet Infect. Dis. 10, 68-69 (2010).
24. Steingart, K. R. et al. Performance of purified antigens for serodiagnosis of pulmonary tuberculosis: a metaanalysis. Clin. Vaccine Immunol. 16, 260-276 (2009).
25. Abebe, F. C., Holm-Hansen, C., Wiker, H. G. & Bjune, G. Progress in serodiagnosis of Mycobacterium tuberculosis infection. Scand. J. Infect. Dis. 66, 176-191 (2007). (Pubitemid 47063204)
26. Special Programme for Research & Training in Tropical Diseases. Laboratory-based evaluation of 19 commercially available rapid diagnostic tests for tuberculosis (WHO, Geneva, 2008).
27. Beyene, D. et al. Serodiagnosis of tuberculous lymphadenitis using a combination of antigens. J. Infect. Dev. Ctries 4, 96-102 (2010).
28. Zhang, S. L. et al. Development and evaluation of a novel multiple-antigen ELISA for serodiagnosis of tuberculosis. Tuberculosis (Edinb.) 89, 278-284 (2009).
29. Kunnath-Velayudhan, S. et al. Dynamic antibody responses to the Mycobacterium tuberculosis proteome. Proc. Natl Acad. Sci. USA 107, 14703-14708 (2010).
30. Davies, D. H. et al. Profiling the humoral immune response to infection by using proteome microarrays: high-throughput vaccine and diagnostic antigen discovery. Proc. Natl Acad. Sci. USA 102, 547-552 (2005). (Pubitemid 40282702)
31. Li, Y. et al. A proteome-scale identification of novel antigenic proteins in Mycobacterium tuberculosis toward diagnostic and vaccine development. J. Proteome Res. 9, 4812-4822 (2010).
32. Weldingh, K., Rosenkrands, I., Okkels, L. M., Doherty, T. M. & Andersen, P. Assessing the serodiagnostic potential of 35 Mycobacterium tuberculosis proteins and identification of four novel serological antigens. J. Clin. Microbiol. 43, 57-65 (2005). (Pubitemid 40096280)
33. Bahk, Y. Y. et al. Antigens secreted from Mycobacterium tuberculosis: identification by proteomics approach and test for diagnostic marker. Proteomics 4, 3299-3307 (2004).
34. Sartain, M. J., Slayden, R. A., Singh, K. K., Laal, S. & Belisle, J. T. Disease state differentiation and identification of tuberculosis biomarkers via native antigen array profiling. Mol. Cell Proteomics 5, 2102-2113 (2006). (Pubitemid 44817022)
35. Agranoff, D. et al. Identification of diagnostic markers for tuberculosis by proteomic fingerprinting of serum. Lancet 368, 1012-1021 (2006). (Pubitemid 44353670)
36. Berry, M. P. et al. An interferon-inducible neutrophildriven blood transcriptional signature in human tuberculosis. Nature 466, 973-977 (2010).
37. Palomino, J. C., Cardoso Leao, S. & Ritacco, V. Tuberculosis 2007: from basic science to patient care. Tuberculosis Textbook [online] http://www. tuberculosistextbook.com/tuberculosis2007.pdf (2007).
38. Flores, L. L., Pai, M., Colford, J. M. Jr & Riley, L. W. In-house nucleic acid amplification tests for the detection of Mycobacterium tuberculosis in sputum specimens: meta-analysis and meta-regression. BMC Microbiol. 5, 55 (2005).
39. Telenti, A. et al. Detection of rifampicin-resistance mutations in Mycobacterium tuberculosis. Lancet 341, 647-650 (1993). (Pubitemid 23083244)
40. Traore, H., Fissette, K., Bastian, I., Devleeschouwer, M. & Portaels, F. Detection of rifampicin resistance in Mycobacterium tuberculosis isolates from diverse countries by a commercial line probe assay as an initial indicator of multidrug resistance. Int. J. Tuberc. Lung Dis. 4, 481-484 (2000). (Pubitemid 30256852)
41. Temple, B. et al. Rate and amplification of drug resistance among previously-treated patients with tuberculosis in Kampala, Uganda. Clin. Infect. Dis. 47, 1126-1134 (2008).
42. Zager, E. M. & McNerney, R. Multidrug-resistant tuberculosis. BMC Infect. Dis. 8, 10 (2008).
43. Daniel, T. M. Antibody and antigen detection for the immunodiagnosis of tuberculosis: why not? What more is needed? Where do we stand today? J. Infect. Dis. 158, 678-680 (1988).
44. Chatterjee, D., Bozic, C. M., McNeil, M. & Brennan, P. J. Structural features of the arabinan component of the lipoarabinomannan of Mycobacterium tuberculosis. J. Biol. Chem. 266, 9652-9660 (1991). (Pubitemid 21906706)
45. Dheda, K. et al. Clinical utility of a commercial LAMELISA assay for TB diagnosis in HIV-infected patients using urine and sputum samples. PLoS ONE 5, e9848 (2010).
46. Patel, V. B. et al. Utility of a novel lipoarabinomannan assay for the diagnosis of tuberculous meningitis in a resource-poor high-HIV prevalence setting. Cerebrospinal Fluid Res. 6, 13 (2009).
47. Boehme, C. et al. Detection of mycobacterial lipoarabinomannan with an antigen-capture ELISA in unprocessed urine of Tanzanian patients with suspected tuberculosis. Trans. R. Soc. Trop. Med. Hyg. 99, 893-900 (2005). (Pubitemid 41511449)
48. Mutetwa, R. et al. Diagnostic accuracy of commercial urinary lipoarabinomannan detection in African tuberculosis suspects and patients. Int. J. Tuberc. Lung Dis. 13, 1253-1259 (2009).
49. Daley, P. et al. Blinded evaluation of commercial urinary lipoarabinomannan for active tuberculosis: a pilot study. Int. J. Tuberc. Lung Dis. 13, 989-995 (2009).
50. Shah, M. et al. Diagnostic accuracy of a urine lipoarabinomannan test for tuberculosis in hospitalized patients in a High HIV prevalence setting. J. Acquir. Immune Defic. Syndr. 52, 145-151 (2009).
51. Lawn, S. D. et al. Urine lipoarabinomannan assay for tuberculosis screening before antiretroviral therapy diagnostic yield and association with immune reconstitution disease. AIDS 23, 1875-1880 (2009).
52. Wishart, D. S. et al. HMDB: the Human Metabolome Database. Nucleic Acids Res. 35, D521-D526 (2007). (Pubitemid 46056263)
53. Beste, D. J. et al. GSMN-TB: a web-based genomescale network model of Mycobacterium tuberculosis metabolism. Genome Biol. 8, R89 (2007).
54. Hippocrates. Aphorisms (translation by Adams, F.) (Dodo Press, Gloucester, UK, 2009).
55. Weetjens, B. J. et al. African pouched rats for the detection of pulmonary tuberculosis in sputum samples. Int. J. Tuberc. Lung Dis. 13, 737-743 (2009).
56. Syhre, M. & Chambers, S. T. The scent of Mycobacterium tuberculosis. Tuberculosis (Edinb.) 88, 317-323 (2008).
57. Spooner, A. D., Bessant, C., Turner, C., Knobloch, H. & Chambers, M. Evaluation of a combination of SIFT-MS and multivariate data analysis for the diagnosis of Mycobacterium bovis in wild badgers. Analyst 134, 1922-1927 (2009).
58. Phillips, M. et al. Breath biomarkers of active pulmonary tuberculosis. Tuberculosis (Edinb.) 90, 145-151 (2010).
59. Syhre, M., Manning, L., Phuanukoonnon, S., Harino, P. & Chambers, S. T. The scent of Mycobacterium tuberculosis - Part II breath. Tuberculosis (Edinb.) 89, 263-266 (2009).
60. Fend, R. et al. Prospects for clinical application of electronic-nose technology to early detection of Mycobacterium tuberculosis in culture and sputum. J. Clin. Microbiol. 44, 2039-2045 (2006). (Pubitemid 43902150)
61. Fend, R. et al. Use of an electronic nose to diagnose Mycobacterium bovis infection in badgers and cattle. J. Clin. Microbiol. 43, 1745-1751 (2005).
62. Knobloch, H., Turner, C., Spooner, A. & Chambers, M. Methodological variability using electronic nose technology for headspace analysis. AIP Conf. Proc. 1137, 327-330 (2009).
63. Knobloch, H., Turner, C., Spooner, A. & Chambers, M. Methodological variation in headspace analysis of liquid samples using electronic nose. Sens. Actuators B Chem. 139, 353-360 (2009).
64. Kolk, A. et al. Electronic-nose technology in diagnosis of TB patients using sputum samples. J. Clin. Microbiol. 48, 4235-4238 (2010).
65. Phillips, M. et al. Volatile biomarkers of pulmonary tuberculosis in the breath. Tuberculosis (Edinb.) 87, 44-52 (2007). (Pubitemid 44960164)
66. Weigl, B., Domingo, G., Labarre, P. & Gerlach, J. Towards non- and minimally instrumented, microfluidics-based diagnostic devices. Lab Chip 8, 1999-2014 (2008).
67. Ikada, Y. & Tsuji, H. Biodegradable polyesters for medical and ecological applications. Macromol. Rapid Commun. 21, 117-132 (2000).
68. Poller, R. C. Reclamation of waste plastics and rubber: recovery of materials and energy. J. Chem. Technol. Biotechnol. 30, 152-160 (1980). (Pubitemid 10122822)
69. Helb, D. et al. Rapid detection of Mycobacterium tuberculosis and rifampin-resistance using on-demand, near patient technology. J. Clin. Microbiol. 48, 229-237 (2009).
70. Banada, P. P. et al. Containment of bioaerosol infection risk by the Xpert MTB/RIF assay and its applicability to point-of-care settings. J. Clin. Microbiol. 48, 3551-3557 (2010).
71. Blakemore, R. et al. Evaluation of the analytical performance of the Xpert MTB/RIF assay. J. Clin. Microbiol. 48, 2495-2501 (2010).
72. Boehme, C. C. et al. Rapid molecular detection of tuberculosis and rifampin resistance. N. Engl. J. Med. 363, 1005-1015 (2010).
73. Van Ness, J., Van Ness, L. K. & Galas, D. J. Isothermal reactions for the amplification of oligonucleotides. Proc. Natl Acad. Sci. USA 100, 4504-4509 (2003). (Pubitemid 36457760)
74. Notomi, T. et al. Loop-mediated isothermal amplification of DNA. Nucleic Acids Res. 28, E63 (2000).
75. Fang, R. et al. Cross-priming amplification for rapid detection of Mycobacterium tuberculosis in sputum specimens. J. Clin. Microbiol. 47, 845-847 (2009).
76. Piepenburg, O., Williams, C. H., Stemple, D. L. & Armes, N. A. DNA detection using recombination proteins. PLoS Biol. 4, e204 (2006).
77. Soo, P. C. et al. A simple gold nanoparticle probes assay for identification of Mycobacterium tuberculosis and Mycobacterium tuberculosis complex from clinical specimens. Mol. Cell. Probes 23, 240-246 (2009).
78. Tan, E. et al. Isothermal DNA amplification coupled with DNA nanosphere-based colorimetric detection. Anal. Chem. 77, 7984-7992 (2005). (Pubitemid 41831983)
79. Mori, Y., Nagamine, K., Tomita, N. & Notomi, T. Detection of loop-mediated isothermal amplification reaction by turbidity derived from magnesium pyrophosphate formation. Biochem. Biophys. Res. Commun. 289, 150-154 (2001). (Pubitemid 33108807)
80. Boehme, C. C. et al. Operational feasibility of using loop-mediated isothermal amplification for diagnosis of pulmonary tuberculosis in microscopy centers of developing countries. J. Clin. Microbiol. 45, 1936-1940 (2007). (Pubitemid 46933929)
81. Lutz, S. et al. Microfluidic lab-on-a-foil for nucleic acid analysis based on isothermal recombinase polymerase amplification (RPA). Lab Chip 10, 887-893 (2010).
82. Hanlon, E. B. et al. Prospects for in vivo Raman spectroscopy. Phys. Med. Biol. 45, R1-R59 (2000). (Pubitemid 30096760)
83. Ozaki, Y., Cho, R., Ikegaya, K., Muraishi, S. & Kawauchi, K. Potential of near-infrared Fouriertransform Raman-spectroscopy in food analysis. Appl. Spectrosc. 46, 1503-1507 (1992).
84. Buijtels, P. C. et al. Rapid identification of mycobacteria by Raman spectroscopy. J. Clin. Microbiol. 46, 961-965 (2008). (Pubitemid 351379987)
85. McNerney, R. et al. Field test of a novel detection device for Mycobacterium tuberculosis antigen in cough. BMC Infect. Dis. 10, 161 (2010).
86. Liu, G. et al. Disposable electrochemical immunosensor diagnosis device based on nanoparticle probe and immunochromatographic strip. Anal. Chem. 79, 7644-7653 (2007). (Pubitemid 47622391)
87. Vo-Dinh, T., Cullum, B. M. & Stokes, D. L. Nanosensors and biochips: frontiers in biomolecular diagnostics. Sens. Actuator B Chem. 74, 2-11 (2001). (Pubitemid 32287936)
88. Jiang, X. H., Liu, W. Q., Chen, J. J. & Lin, X. Q. Application of DNA nanotechnology. Prog. Chem. 19, 608-613 (2007).
89. Qin, D. et al. Fluorescent nanoparticle-based indirect immunofluorescence microscopy for detection of Mycobacterium tuberculosis. J. Biomed. Biotechnol. 2007, 89364 (2007).
90. Yager, P. et al. Microfluidic diagnostic technologies for global public health. Nature 442, 412-418 (2006). (Pubitemid 44264785)
91. Baptista, P. V., Koziol-Montewka, M., Paluch-Oles, J., Doria, G. & Franco, R. Gold-nanoparticle-probe-based assay for rapid and direct detection of Mycobacterium tuberculosis DNA in clinical samples. Clin. Chem. 52, 1433-1434 (2006). (Pubitemid 43956043)
92. Lee, H., Sun, E., Ham, D. & Weissleder, R. Chip-NMR biosensor for detection and molecular analysis of cells. Nature Med. 14, 869-874 (2008).
93. Chun, A. L. Nanoparticles offer hope for TB detection. Nature Nanotech. 4, 698-699 (2009).
94. Harrington M, Morgan S. & Syed, J. 2009 Report on Tuberculosis Research Funding Trends, 2005-2008 2nd edn (Treatment Action Group, New York, 2010).
95. Peeling, R. W. & Mabey, D. Point-of-care tests for diagnosing infections in the developing world. Clin. Microbiol. Infect. 16, 1062-1069 (2010).
96. Pai, M., Minion, J., Steingart, K. & Ramsay, A. New and improved tuberculosis diagnostics: evidence, policy, practice, and impact. Curr. Opin. Pulm. Med. 16, 271-284 (2010).
97. WHO. The global plan to stop TB 2011-2015: transforming the fight towards elimination of tuberculosis. (WHO, Geneva, 2010).
98. Nathanson, C. M. et al. The TDR Tuberculosis Specimen Bank: a resource for diagnostic test developers. Int. J. Tuberc. Lung Dis. 14, 1461-1467 (2010).